Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

111.45 -1.09 (-0.97%)
Streaming Delayed Price Updated: 12:31 PM EDT, Sep 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
45 46 Next >
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Looking For Ebola Virus Meds? WHO Recommends These Two Antibody Treatments
 
Via Benzinga
Covid Stocks Pfizer, Moderna, Novavax Face Their Next Challenge, And It's Worth Billions
How they handle an upcoming shift in payments will be telling for their tailwind. 
Via Investor's Business Daily
Caribou's Blood Cancer Candidate Shows Response Rates Better Than Novartis,' This Analyst Writes
 
Via Benzinga
Can Faraday Future (FFIE) Stock Turn Its Cash Crunch Around?
Faraday Future (FFIE) stock is on the move Tuesday as investors react to news of a new funding agreement to keep the business going. 
Via InvestorPlace
What Is Going on With Gilead Sciences (GILD) Stock Today?
GILD stock is the focus of not just one but two news items today, and traders are trying to decide if they're bullish or bearish. 
Via InvestorPlace
Gilead Sciences Bets $400M On Inflammatory Diseases Focused UK Based Firm
 
Via Benzinga
Gilead Sciences' Q2 Beats Street View On Robust Oncology, HIV Product Sales
 
Via Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $1,400 Today
  Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 6.41% on an annualized basis producing an average annual return of 14.28%. Currently, Gilead Sciences has a market... 
Via Benzinga
SoftBank Just Gave Nu Holdings (NU) Stock a Big Boost
Nu Holdings (NU) stock is on the rise Tuesday as investors react to news of SoftBank (SFTBY) taking a stake in the banking company. 
Via InvestorPlace
After Surprise Overall Survival Data In Metastatic Breast Cancer, Gilead Takes Complete Rights To Trodelvy
 
Via Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
 
Via Benzinga
Why Gilead Sciences Stock Jumped 5% Today
Gilead Sciences Inc (NASDAQ: GILD) shares closed higher Monday after the company announced statistically significant and clinically meaning 
Via Benzinga
Gilead Boosts 2022 Guidance On The Back Of Its Covid Treatment
The company now expects the intravenous drug to generate $2.5 billion in sales this year. 
Via Investor's Business Daily
Gilead's Biktarvy Demonstrates High Efficacy In HIV/HBV Coinfection Patients
 
Via Benzinga
European Commission Signs COVID-19 Drug Procurement Deal With Gilead
 
Via Benzinga
Daily Stock Analysis: Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. 
Via Talk Markets
Snap, Gilead Sciences And Some Other Big Stocks Moving Higher On Monday
Magic Empire Global Limited (NASDAQ: MEGL) shares climbed 80.9% to $14.87 on volatility following the company's IPO earlier this month. 
Via Benzinga
Gilead Shares Climb On Positive Interim Analysis From Late-Stage Breast Cancer Study
Gilead Sciences, Inc. (NASDAQ: GILD) announced positive results from the second interim analysis of the key secondary endpoint of overall survival (OS) in the Phase 3 TROPiCS-02 study evaluating... 
Via Benzinga
7 Growth Stocks to Buy After a 20% Correction
These are among the best growth stocks to buy now. ADBE, AMD, GILD, LOW, MELI, MP, and PYPL are poised to benefit from strong trends in 2022. 
Via InvestorPlace
3 Best Funds for Aggressive Investors
These are the three best funds for aggressive investors. ETFs like BUG, RYT, and BBH can make great investments in the rest of the year. 
Via InvestorPlace
August 2022 Stock Considerations
A look at August stock considerations. 
Via Talk Markets
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Recession Investing: 5 High Yield Dividend Stocks For A Downturn
As the healthcare industry absorbed enormous amounts of profits during the Covid-19 pandemic, many healthcare companies will be increasing shareholder distributions to entice investors to buy their... 
Via Benzinga
Gilead Sciences: Q2 Earnings Insights
Gilead Sciences (NASDAQ:GILD) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Gilead Sciences beat estimated... 
Via Benzinga
Australia's Central Bank Has Raised Its Interest Rate. Business Activity In Europe Is Falling
Australia's Central Bank raised its interest rate by 50 basis points to 1.85%. The Bank said in a statement that it attaches great importance to getting inflation back into the 2-3 percent range over... 
Via Talk Markets
Recap Of Thursday's Biotech Catalysts - End of The Day Summary
 
Via Benzinga
8 Dividend ETFs to Buy and Hold Forever
Dividend ETFs like these eight provide investors with a steady source of income while they wait for the stock market to recover. 
Via InvestorPlace
Recap Of Friday's Biotech Catalysts - End Of The Day Summary
 
Via Benzinga
7 Best Pharmaceutical Stocks to Buy Now
These investments represent the best pharmaceutical stocks. Each offers incredible upside potential in the post-pandemic world. 
Via InvestorPlace
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
45 46 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.